When the pandemic struck, biotechnology chief executives suddenly faced questions about how to keep their workers safe, their research moving and their budgets intact.
I stood in front of 15 skeptical parents and prepared to sell them on an improbable mission.
They had all signed their daughters up for the first-grade basketball team. I would be coaching that team. And I was here to advise them that this would not be the type of experience their six- and seven-year-olds were used to.
This blog was written by Josh Brumm, CEO of Dyne Therapeutics, as part of the From The Trenches feature of LifeSciVC.
What a difference a little time makes.
When Bruce originally encouraged me to be a contributor to From The Trenches, life was “the way it used to be.” And as Atlas’ Head of Talent, I mused about writing on topics related to Executive Search, Leadership, and Venture in general. But in what feels like a blink of an eye, the world feels (and is) incredibly different. With the COVID-19 pandemic impacting our lives and consciousness, now may not be time to discuss topics that seem far from important.
This blog was written by Andrea DiMella, VP and Head of Talent at Atlas Venture, as part of the From The Trenches feature of LifeSciVC.
Two years ago, Accent Therapeutics got off a $40 million series A to target RNA-modifying proteins in cancer; now, in the middle of a pandemic, it’s still managed to bring in a respectable $63 million second funding round.
When I discussed the topic of writing about my experience as an immigrant biotech CEO with Bruce Booth, I had not yet imagined how the global COVID-19 pandemic would change our lives. I initially hesitated to submit it, now that we are in the midst of this crisis – after all there are more important topics we should focus on. But, maybe it is good to get one’s mind off COVID-19 for a few moments.
This blog post was written by Gerhard Koenig, CEO of Arkuda Therapeutics, as part of the From The Trenches feature of LifeSciVC.